Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephan A Grupp

Showing results (221-230 of 238) with videos related to

Pageof 24
Sort By:
Blood Advances|May 4, 2023
The utility of biomarkers in acute GVHD prognosticationNikolaos Spyrou, Yu Akahoshi, Francis Ayuk, et al.
Transplantation and Cellular Therapy|September 2, 2024
Differences in Acute Graft-Versus-Host Disease (GVHD) Severity and Its Outcomes Between Black and White PatientsCarlos A Ortega Rios, Muna Qayed, Aaron M Etra, et al.
Nature|April 23, 2024
Publisher Correction: FOXO1 is a master regulator of memory programming in CAR T cellsAlexander E Doan, Katherine P Mueller, Andy Y Chen, et al.
Nature|April 10, 2024
FOXO1 is a master regulator of memory programming in CAR T cellsAlexander E Doan, Katherine P Mueller, Andy Y Chen, et al.
Blood|July 5, 2024
Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHDYu Akahoshi, Nikolaos Spyrou, Daniela Weber, et al.
The New England Journal of Medicine|February 1, 2018
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic LeukemiaShannon L Maude, Theodore W Laetsch, Jochen Buechner, et al.
Blood Advances|February 7, 2024
Flares of acute graft-versus-host disease: a Mount Sinai Acute GVHD International Consortium analysisYu Akahoshi, Nikolaos Spyrou, Matthias Hoepting, et al.
Blood Advances|June 14, 2023
Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHDYu Akahoshi, Nikolaos Spyrou, William J Hogan, et al.
Transplantation and Cellular Therapy|February 6, 2024
A Day 14 Endpoint for Acute GVHD Clinical TrialsNikolaos Spyrou, Yu Akahoshi, Steven Kowalyk, et al.
Nature Medicine|April 23, 2021
Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cellsNathan Singh, Noelle V Frey, Boris Engels, et al.
Pageof 24

Showing results (221-230 of 238) with videos related to

Sort By:
Pageof 24
Blood Advances|May 4, 2023
The utility of biomarkers in acute GVHD prognosticationNikolaos Spyrou, Yu Akahoshi, Francis Ayuk, et al.
Transplantation and Cellular Therapy|September 2, 2024
Differences in Acute Graft-Versus-Host Disease (GVHD) Severity and Its Outcomes Between Black and White PatientsCarlos A Ortega Rios, Muna Qayed, Aaron M Etra, et al.
Nature|April 23, 2024
Publisher Correction: FOXO1 is a master regulator of memory programming in CAR T cellsAlexander E Doan, Katherine P Mueller, Andy Y Chen, et al.
Nature|April 10, 2024
FOXO1 is a master regulator of memory programming in CAR T cellsAlexander E Doan, Katherine P Mueller, Andy Y Chen, et al.
Blood|July 5, 2024
Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHDYu Akahoshi, Nikolaos Spyrou, Daniela Weber, et al.
The New England Journal of Medicine|February 1, 2018
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic LeukemiaShannon L Maude, Theodore W Laetsch, Jochen Buechner, et al.
Blood Advances|February 7, 2024
Flares of acute graft-versus-host disease: a Mount Sinai Acute GVHD International Consortium analysisYu Akahoshi, Nikolaos Spyrou, Matthias Hoepting, et al.
Blood Advances|June 14, 2023
Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHDYu Akahoshi, Nikolaos Spyrou, William J Hogan, et al.
Transplantation and Cellular Therapy|February 6, 2024
A Day 14 Endpoint for Acute GVHD Clinical TrialsNikolaos Spyrou, Yu Akahoshi, Steven Kowalyk, et al.
Nature Medicine|April 23, 2021
Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cellsNathan Singh, Noelle V Frey, Boris Engels, et al.
Pageof 24